JulesEliHarrisMD

PubMed

• 27 citations
  Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal canal: An eastern cooperative oncology group...
  Minaxi Jhawer, Sridhar Mani, Myrto Lefkopoulou, Richard G. Hahn, Jules E. Harris, Paul J. Catalano, Daniel G. Haller> ;Investigational New Drugs. 2006 Apr 22
• 45 citations
  Elevated serum heparanase-1 levels in patients with pancreatic carcinoma are associated with poor survival.
  Roderick M. Quiros, Geetha Rao, Janet M. D. Plate, Jules E. Harris, Gregory J. Brunn, Jeffrey L. Platt, Paolo Gattuso, Richard A. Prinz, Xiulong Xu> ;Cancer. 2006 Feb 1
• 5 citations
  Immunobiotherapy directed against mutated and aberrantly expressed gene products in pancreas cancer.
  Janet M. D. Plate, Jules E. Harris> ;Journal of Cellular Biochemistry. 2005 Apr 15
• 138 citations
  Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas
  Janet M. D. Plate, Aileen E. Plate, Susan Shott, Susan Bograd, Jules E. Harris> ;Cancer Immunology, Immunotherapy. 2005 Mar 22
• 6 citations
  Disparate forms of MK 886-induced programmed death in BCL-2 (+) blood and BCL-2 (-) solid cancer cells and a putative "nuclear" Ca2+ channel: "soil" trumps "seed"?
  Kenning M. Anderson, Marvin Rubenstein, Paulus Tsui, Jules E. Harris> ;Medical Hypotheses. 2005 Jan 1
• 3 citations
  Reactive oxygen species and redox-induced programmed cell death due to MK 886: cells ("soil") "trump" agent ("seed").
  Ken M. Anderson, Marvin Rubenstein, Waddah A. Alrefai, Dudeja P, Paulus Tsui, Patrick Guinan, Jules E. Harris> ;In Vivo. 2005 Jan 1
• 3 citations
  Acute changes in U937 nuclear Ca2+ preceding type 1 "apoptotic" programmed cell death due to MK 886.
  Ken M. Anderson, Marvin Rubenstein, Waddah A. Alrefai, Pradeep K. Dudeja, P. Tsui, Jules E. Harris> ;Anticancer Research. 2004 Sep 1
• 25 citations
  Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the eastern cooperative oncology group.
  Robert C. Shepard, Donna E. Levy, Jordan Berlin, Keith Stuart, Jules E. Harris, Victor Aviles, James P. Thomas, Al B. Benson> ;Oncology. 2004 Jan 1
• 2 citations
  Phase II Study of Cisplatin and 5-Fluorouracil (PF) and Mitomycin C, Vincristine, Cisplatin and 5-Fluorouracil (MVPF) in Patients with Metastatic Large Bowel Cancer: A...
  Kishan J. Pandya, Myrto Lefkopoulou, Nicholas J. Petrelli, David J. Vaughn, Thomas J. Smith, Jules E. Harris, Daniel G. Haller> ;Oncology. 2004 Jan 1
• 9 citations
  Caspase-dependent and -independent panc-1 cell death due to actinomycin D and MK 886 are additive but increase clonogenic survival.
  Kenning M. Anderson, Waddah A. Alrefai, Philip Bonomi, Thomas M. Seed, Pradeep K. Dudeja, Yunming Hu, Jules E. Harris> ;Experimental Biology and Medicine. 2003 Sep 1
• 12 citations
  Phase III study of combined chemohormonal therapy in metastatic prostate cancer (ECOG 3882): an Eastern Cooperative Oncology Group study.
  Andrea Leaf, Kathleen J. Propert, Chris Corcoran, Paul J. Catalano, Donald L. Trump, Jules E. Harris, Thomas E. Davis> ;Medical Oncology. 2003 Jan 1
• Addendum to a note regarding the success of biological and medical science.
  Kenning M. Anderson, Jules E. Harris> ;Medical Hypotheses. 2002 Jul 1
• 9 citations
  Increased cytosol Ca2+ and type 1 programmed cell death in Bcl-2-positive U937 but not in Bcl-2-negative PC-3 and Panc-1 cells induced by the 5-lipoxygenase inhibitor ...
  Kenning M. Anderson, W.A. Alrefai, P.K. Dudeja, S. Jadko, Philip Bonomi, Y. Hu, D. Ou, Jules E. Harris> ;Prostaglandins, Leukotrienes, and Essential Fatty Acids. 2002 Apr 1
• 2 citations
  MK 886 functions as a radiomimetic agent: genomic responses related to oxidative stress, the cell cycle, proliferation and programmed cell death in Panc-1 cells.
  Ken M. Anderson, Waddah Alrefai, C.A. Anderson, Philip Bonomi, Jules E. Harris> ;Advances in Experimental Medicine and Biology. 2002 Jan 1
• 4 citations
  A response of Panc-1 cells to cis-platinum, assessed with a cDNA array.
  Ken M. Anderson, Waddah A. Alrefai, C. A. Anderson, Y. Ho, S. Jadko, D. Ou, Y. B. Wu, Jules E. Harris> ;Anticancer Research. 2002 Jan 1
• 5 citations
  Is induction of type 2 programmed death in cancer cells from solid tumors directly related to mitochondrial mass
  Kenning M. Anderson, Jules E. Harris> ;Medical Hypotheses. 2001 Jul 1
• 2 citations
  Selected features of nonendocrine pancreatic cancer.
  Ken M. Anderson, Jules E. Harris> ;Experimental Biology and Medicine. 2001 Jun 1
• 6 citations
  The mode of cell death in H-358 lung cancer cells cultured with inhibitors of 5-lipoxygenase or the free radical spin trap, NTBN
  Ou D, Philip Bonomi, W Jao, S. Jadko, Jules E. Harris, Kenning M. Anderson> ;Cancer Letters. 2001 May 26
• 1 citations
  Comments on the unreasonable effectiveness of the biological and especially medical sciences.
  Kenning M. Anderson, Jules E. Harris> ;Medical Hypotheses. 2001 Apr 1
• 6 citations
  Comparison of 5-fluorouracil alone, 5-fluorouracil with levamisole, and 5-fluorouracil with hepatic irradiation in the treatment of patients with residual, nonmeasurab...
  Robert S. Witte, Avital Cnaan, Edward G. Mansour, Edward Barylak, Jules E. Harris, Allan J. Schutt> ;Cancer. 2001 Mar 1
• Adjuvant and Neoadjuvant Therapies of Pancreatic Cancer: A Review.
  Jules Harris, Howard Bruckner> ;International Journal of Gastrointestinal Cancer. 2001 Jan 1
• Adjuvant and neoadjuvant therapies of pancreatic cancer: a review.
  J Harris, H Bruckner> ;International Journal of Pancreatology. 2001 Jan 1
• 11 citations
  A genomic response of H-358 bronchiolar carcinoma cells to MK 886, an inhibitor of 5-lipoxygenase, assessed with a cDNA array.
  Kenning M. Anderson, Waddah A. Alrefai, Bonomi Pa, C.A. Anderson, Pradeep K. Dudeja, Jules E. Harris> ;Anticancer Research. 2000 Jul 1
• 2 citations
  Widespread countervailing genomic responses induced by chemotherapy or radiation as a cause of therapeutic failure.
  Kenning M. Anderson, W.A. Alrefai, C.A. Anderson, Philip Bonomi, Jules E. Harris> ;Medical Hypotheses. 2000 Jun 1
• 63 citations
  A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an Eastern Cooperative Oncology Group Study (E3296).
  Jordan Berlin, Sudeshna Adak, David J. Vaughn, David Flinker, Lawrence S. Blaszkowsky, Jules E. Harris, Al B. Benson> ;Oncology. 2000 Apr 1
• Join now to see all